Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma

Nature Genetics

Volumn 21, Issue 1, 1999, Pages 128-132

  Liu, Ling ^a   Dilworth, David ^b   Gao, Luzhang ^a   Monzon, Jose ^a   Summers, Ann ^c   Lassam, Norman ^a,b   Hogg, David ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHROMOSOME 9P; CODON; GENE LOCUS; GENE MUTATION; HAPLOTYPE; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL;

5' UNTRANSLATED REGIONS; ALLELES; CELL LINE, TRANSFORMED; CODON, INITIATOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GUANINE; HUMANS; MALE; MELANOMA; MUTATION; PEDIGREE; PROTEIN BIOSYNTHESIS; THYMINE; TRANSCRIPTION, GENETIC;

EID: 0032900535     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/5082     Document Type: Article

References (25)

1. Bergman, W., Gruis, N.A., Sandkuijl, L.A. & Frants, R.R. Genetics of seven Dutch familial atypical multiple mole-melanoma syndrome families: a review of linkage results including chromosomes 1 and 9. J. Invest. Dermatol. 103, 122S-125S (1994).
2. Goldstein, A.M. et al. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am. J. Hum. Genet. 54, 489-496 (1994).
3. Bale, S.J., Chakravarti, A. & Greene, M.H. Cutaneous malignant melanoma and familial dysplastic nevi: evidence for autosomal dominance and pleiotropy. Am. J. Hum. Genet. 38, 188-196 (1986).
4. Cannon-Albright, L.A. et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258, 1148-1152 (1992).
5. Cannon-Albright, L.A. et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res. 54, 6041-6044 (1994).
6. Goldstein, A.M., Fraser, M.C., Clark, W.H. Jr & Tucker, M.A. Age at diagnosis and transmission of invasive melanoma in 23 families with cutaneous malignant melanoma/dysplastic nevi. J. Natl Cancer. Inst. 86, 1385-1390 (1994).
7. Goldstein, A.M. & Tucker, M.A. Genetic epidemiology of familial melanoma. Dermatol. Clin. 13, 605-612 (1995).
8. Hogg, D. et al. Role of the cyclin-dependent kinase inhibitor CDKN2A in familial melanoma. J. Cutan. Med. Surg. 2, 172-179 (1998).
9. Hayward, N.K. The current situation with regard to human melanoma and genetic inferences. Curr. Opin. Oncol. B, 136-142 (1996).
10. Kamb, A. Cell-cycle regulators and cancer. Trends Genet. 11, 136-140 (1995).
11. Sherr, C.J. & Roberts, J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163 (1995).
12. Sherr, C.J. Cancer cell cycles. Science 274, 1672-1677 (1996).
13. Hussussian, C.J. et al. Germline p16 mutations in familial melanoma. Nature Genet. 8, 15-21 (1994).
14. Kamb, A. et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8, 23-26 (1994).
15. Gruis, N.A., Sandkuijl, L.A., van der Velden, P.A., Bergman, W. & Frants, R.R. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res. 5, 169-177 (1995).
16. Holland, E.A. et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11, 2289-2294 (1995).
17. Walker, G.J. et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum. Mol. Genet. 4, 1845-1852 (1995).
18. Liu, L. et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11, 405-412 (1995).
19. FitzGerald, M.G. et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. Natl Acad. Sci. USA 93, 8541-8545 (1996).
20. Monzon, J. et al. CDKN2A mutations in multiple primary melanomas. N. Engl. J. Med. 338, 879-887 (1998).
21. Bergenhem, N.C., Venta, P.J., Hopkins, P.J., Kim, H.J. & Tashian, R.E. Mutation creates an open reading frame within the 5′ untranslated region of macaque erythrocyte carbonic anhydrase (CA) I mRNA that suppresses CA I expression and supports the scanning model for translation. Proc. Natl Acad. Sci. USA 89, 8798-8802 (1992).
22. Krude, H. et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nature Genet. 19, 155-157 (1998).
23. Pollock, P.M. et al. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum. Mutat. 11, 424-431 (1998).
24. MacGeoch, C. et al. Genetic heterogeneity in familial malignant melanoma. Hum. Mol. Genet. 3, 2195-2200 (1994).
25. Borg, A. et al. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res. 56, 2497-2500 (1996).